» Articles » PMID: 18339839

Rictor and Integrin-linked Kinase Interact and Regulate Akt Phosphorylation and Cancer Cell Survival

Overview
Journal Cancer Res
Specialty Oncology
Date 2008 Mar 15
PMID 18339839
Citations 121
Authors
Affiliations
Soon will be listed here.
Abstract

An unbiased proteomic screen to identify integrin-linked kinase (ILK) interactors revealed rictor as an ILK-binding protein. This finding was interesting because rictor, originally identified as a regulator of cytoskeletal dynamics, is also a component of mammalian target of rapamycin complex 2 (mTORC2), a complex implicated in Akt phosphorylation. These functions overlap with known ILK functions. Coimmunoprecipitation analyses confirmed this interaction, and ILK and rictor colocalized in membrane ruffles and leading edges of cancer cells. Yeast two-hybrid assays showed a direct interaction between the NH(2)- and COOH-terminal domains of rictor and the ILK kinase domain. Depletion of ILK and rictor in breast and prostate cancer cell lines resulted in inhibition of Akt Ser(473) phosphorylation and induction of apoptosis, whereas, in several cell lines, depletion of mTOR increased Akt phosphorylation. Akt and Ser(473)P-Akt were detected in ILK immunoprecipitates and small interfering RNA-mediated depletion of rictor, but not mTOR, inhibited the amount of Ser(473)P-Akt in the ILK complex. Expression of the NH(2)-terminal (1-398 amino acids) rictor domain also resulted in the inhibition of ILK-associated Akt Ser(473) phosphorylation. These data show that rictor regulates the ability of ILK to promote Akt phosphorylation and cancer cell survival.

Citing Articles

Ternary Complex Components Responsible for Rapid LDL Internalization as Biomarkers for Breast Cancer Associated with Proliferation and Early Recurrence.

McDonald E, Pan T, Pant D, Troester M, Kossenkov A, Mankoff D Cancer Res Commun. 2025; 5(2):226-239.

PMID: 39804138 PMC: 11791746. DOI: 10.1158/2767-9764.CRC-23-0562.


amplification is associated with Rictor membrane staining and does not correlate with PD-L1 expression in lung squamous cell carcinoma.

Krencz I, Sztankovics D, Sebestyen A, Papay J, Danko T, Moldvai D Pathol Oncol Res. 2024; 30:1611593.

PMID: 38706776 PMC: 11066283. DOI: 10.3389/pore.2024.1611593.


The mTORC2 signaling network: targets and cross-talks.

Ragupathi A, Kim C, Jacinto E Biochem J. 2024; 481(2):45-91.

PMID: 38270460 PMC: 10903481. DOI: 10.1042/BCJ20220325.


An Updated Review on Developing Small Molecule Kinase Inhibitors Using Computer-Aided Drug Design Approaches.

Li L, Liu S, Wang B, Liu F, Xu S, Li P Int J Mol Sci. 2023; 24(18).

PMID: 37762253 PMC: 10530957. DOI: 10.3390/ijms241813953.


Dysregulation of mTOR by tau in Alzheimer's disease.

Bloom G, Norambuena A Cytoskeleton (Hoboken). 2023; 81(1):30-34.

PMID: 37638691 PMC: 10919542. DOI: 10.1002/cm.21782.